39 results about "Plasmodium vivax" patented technology

Novel hybrid fusion peptides are disclosed. The novel peptides are formed by the fusion of two or more components. One component is a peptide sequence or variant of a peptide sequence derived from a malaria parasite merozoite peptide which has affinity for and binding capability to red blood cells.

In particular segments of the glycophorin binding peptide 130 (GBP130), are preferred for the first component. Also disclosed are alternative first components, the glycophorin binding peptide homologues (GBPH), or the erythrocyte binding antigen 175 (EBA175), or the plasmodium vivax Duffy receptor or the pre major merozoite surface antigen PMMSA or the (P200) peptide.

The first component peptide is fused to all or part of a peptide segment derived from the CD4 molecule or part thereof or variant thereof which shows binding affinity for the HIV virus.

The resulting fusion peptide being exemplified as

• NH2-CD4-GBP130-COOH
• 1-371 201-774

Also disclosed are the methods of manufacture and means to use the novel hybrid peptides as clinical agents to treat, prevent or test for HIV infection.

Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any strain of P. vivax.

The invention discloses a plasmodium vivax PvMSP1 recombinant antigenic protein, which is protein of which the amino acid sequence is shown in SEQ ID NO:1 which has glycophosphatidylinositol (GPI) anchor and epidermal growth factor-like (EGF-like) structure domain. Furthermore, the invention also discloses a preparation method of the recombinant antigenic protein, which comprises the steps of amplifying a plasmodium vivax PvMSP1 gene sequence, constructing and identifying recombinant plasmid, inducibly expressing and purifying recombinant protein and the like. Experiments prove that the PvMSP1 recombinant antigenic protein has the advantages of high sensitivity, strong specificity and the like to assay of the serum antibody of a plasmodium vivax infected patient, and has a wide application prospect in the aspect of plasmodium vivax epidemiological investigation.

The invention relates to a geographically-specific Plasmodium vivax molecule marker, and its application in strain tracing. The molecule marker includes a Plasmodium vivax circumsporozoite protein center replication region reflecting mosquito infection differences of different media, a height polymorphism microsatellite reflecting mutation, migration and genetic drift, and a drug resistance related gene mutation reflecting the population positivity selection of drug control. Results show that each of a Plasmodium vivax circumsporozoite protein center replication region sequence, dihydrofolate reductase SNP, dihydrobiopterin synthetase SNP, a neutral microsatellite and the like has a geographic specificity, and can be used as a classification index in tracing detection.

The present invention provides isolated polypeptides useful in the treatment and prevention of malaria caused by Plasmodium falciparum or P. vivax. In particular, the polypeptides are derived from the binding domains of the proteins in the EBL family as well as the sialic acid binding protein (SABP) on P. falciparum merozoites. The polypeptides may also be derived from the Duffy antigen binding protein (DABP) on P. vivax merozoites.

The invention discloses an adenosine monophosphate-protected gold-silver alloy nanocluster fluorescence probe, and an application thereof in the detection of Plasmodium vivax lactate dehydrogenase, and belongs to the technical field of fluorescence probes. The fluorescence probe has the advantages of simple structure, easiness in synthesis, strong stability and good biocompatibility, and can generate large linear fluorescence enhanced response to the Plasmodium vivax lactate dehydrogenase (PvLDH). The response has a wide detection range (0 to 1.0 *10<-6> mol/L) and a high sensitivity, and thedetection limit can reach 3.7 ng/mL. An adjuvant Al<3+> is introduced, so the probe can completely distinguish the Plasmodium vivax lactate dehydrogenase and other types of lactate dehydrogenases. Thedetection method of the invention has the advantages of high speed, simplicity in operation, stable signal, high sensitivity, no pretreatment, and no complicated detection instruments.

A transcriptional activator of T. gondii is provided which comprises the tetracycline repressor (TetR) operatively linked to a transacting factor of T. gondii. Strains of T. gondii transformed with a vector containing such a transactivator may be used to prepare vaccine compositions or to identify essential genes in the parasite. The system provided may be useful in other Apicomplexan species such as Plasmodium falciparum, Plasmodium vivax, Plasmodium berghei, Plasmodium yoelii, Plasmodium knowlesi, Trypanosoma brucei, Entamoeba histolytica, and Giardia lambia.

The present invention relates to an immunoassay and diagnostic reagent for malaria by using antigens of malarial Protozoa. More preferably, the present invention relates to an immunoassay and diagnostic reagent for malaria which detect malaria-specific antibodies in blood by using Merozoite Surface Protein of Plasmodium vivax. The immunoassay and diagnostic reagent detecting malaria-specific antibodies in blood according to the present invention have high specificity and sensitivity and are useful in diagnosing a type of malaria where latent period is long and number of Protozoa in blood if few. Also, the present invention relates to a preparation method of the surface protein of malarial Protozoa using yeast or E. Coli. Preferably, the present invention provides an expression vector comprising genes of Merozoite Surface Protein of Plasmodium Vivax and histidine residues, as well as transformants transformed with the expression vector. Also, the present invention provides a method for preparing Merozoite Surface Protein of malarial Protozoa by using the transformant. The surface protein Merozoite Surface Protein of malarial Protozoa prepared from yeast or E. Coli transformant according to the present invention has high sensitivity and specificity to antibody as well as high purity. Also, the surface protein prepared by the preparation method of the present invention has markedly low pseudo-positive signals, and is useful in diagnosing malaria.

A combination kit for the treatment of malaria caused by Plasmodium vivax (P. vivax) having individual doses of an anti-malarial agent, 3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I) in the form of capsules; individual doses of the anti-malarial agent, chloroquine in the form of tablets; and instruction material for the administration of the two anti-malarial drugs. The combination kit is particularly suited for a 6 days treatment regimen where the treatment is rendered by five tablets containing 500 mg of chloroquine phosphate (equivalent to 300 mg base), three to be taken on day one and one each on days two and three; and five capsules containing 25 mg of 3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I), one each to be taken on days two to six.

The present disclosure gives description of a method used for the detection and quantification of malarial infection caused either by Plasmodium falciparum or Plasmodium vivax using nucleic acids isolated from blood samples by employing Oligonucleotide probes. The method employed here for detection is by Real time PCR.

Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against Plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against Plasmodium vivax are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.

The invention relates to the field of parasitology. Methods and peptidic substrate for screening and identifying inhibitors of Plasmodium are described. Also described are compounds identified by these screening methods, including more particularly inhibitors of Plasmodium subtilisin-like proteases. The invention also concerns anti-malaria compounds, anti-malaria compositions, and uses thereof for preventing, treating, improving, and/or alleviating a Plasmodium infection in a subject, and more Plasmodium vivax and/or by Plasmodium falciparum human infections.

The invention relates to a recombinant or synthetic polypeptide characterised in that it includes at least three consecutive repetitions of nonapeptide A N G A G X1 Q X2 X3, in which X1 is selected from D and N, X2 is selected from P and A and X2 is selected from G and A. The inventive polypeptide also preferably includes at least two (2) consecutive repetitions of sequence GDRADGQPA and in an even more preferable embodiment the polypeptide includes an amino-terminal region, a C-terminal region and/or the ptt30 fragment. The invention also relates to malaria vaccines characterised in that they include said peptides.

A candidate subunit for a vaccine against malaria caused by P. vivax, known as Pv200L, which is based on N-terminal end portions of the P. vivax MSP-1 protein is disclosed. The subunit is designed for use alone or in formulations, combined with other subunits. The production of recombinant prototypes of the subunit and the design of a production process that can be scaled up for mass production thereof is also disclosed.

The present invention relates novel methods and compositions for blocking transmission of Plasmodium vivax which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of Plasmodium vivax zygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.

The present invention relates novel methods and compositions for blocking transmission of Plasmodium vivax which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of Plasmodium vivax zygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.

The invention relates to a rapid and sensitive detection method for plasmodium vivax. The detection method integrates two powerful molecular biology techniques, namely, polymerase chain reaction (PCR) and microarray, a PCR-hybridized probe is directly fixed to hybridization cabins of the microarray and the probe and a PCR reaction chamber are located at the same chip. The detection method comprises the following steps of carrying out bacteria-proliferating treatment on a sample, extracting a DNA liquid, carrying out PCR amplification, hybridizing, cleaning and interpreting the results. By the detection method, plasmodium vivax can be rapidly and sensitively detected, the detection efficiency of frontline inspection and quarantine personnel of import and export ports can be greatly improved, the workload can be reduced, the problem of possibly missed positive inspections in the traditional detection methods can be furthest solved and thus the malaria parasite epidemic situation is furthest prevented.

The invention discloses primers and method for identifying genetic polymorphism of Plasmodium vivax PvMSP-3alpha. The primers include an upstream primer (shown as SEQ ID NO: 1) and a downward primer (shown as SEQ ID NO: 2). The specific primers are designed according to regional characteristics of genetic polymorphism; a DNA fragment containing a conserved region and a polymorphic region is acquired by PCR (polymerase chain reaction); whether PvMSP-3alpha gene mutates can be identified through sequencing and analysis; the gene type being wild or mutant can be distinguished then. In addition, the invention also discloses application of the specific primers for identifying genetic polymorphism of Plasmodium vivax PvMSP-3alpha in the preparation of detection tools for identifying genetic polymorphism of Plasmodium vivax PvMSP-3alpha.